Miracell, a stem cell-focused biotechnology company, announced that clinical results have demonstrated significant cognitive ...
CellProthera will use Quintessence’s DACSTM flotation‑based cell sorting platform for its potential to enhance therapeutic purity and preserve stem cell phenotype for CD34+-based cell therapy Mulhouse ...
Study in adults and children with aplastic anemia identifies parallel evolutionary pathways used by hematopoietic stem cells ...
CellProthera, a clinical-stage biotechnology company developing regenerative cell therapies for ischemic diseases, today announced the appointment of Jérôme Hirtzlin and Anne de la Fortelle to its ...
Aplastic anemia is a rare, life-threatening blood disorder where patients are unable to make enough blood cells due to the ...
Patients treated with dilanubicel demonstrated faster hematopoietic recovery and had a markedly lower incidence of severe acute GVHD. HealthDay News — Adding dilanubicel, a cryopreserved, cord blood ...
Two papers published in The New England Journal of Medicine highlight the potential of gene editing for treatment of sickle ...
MedPage Today on MSN
Pooled Cord Blood Transplants Achieve Near-Perfect Results in Early Trial
Disease-free survival of 96% with no severe GVHD in acute leukemia, other blood cancers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results